Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.

The GALAXY trial is a Phase 2b/3 program designed to compare single agent docetaxel versus docetaxel plus ganetespib, a potent and selective Hsp90 inhibitor, as second-line treatment of advanced non-small cell lung cancer. The presentation will review prior results highlighted at the 2012 Congress of the European Society for Medical Oncology (ESMO) last September.